Plain-English translation of NCT07575984 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing ®, a medication given intravenously (through an IV) and by mouth to treat people in the early hours and days after an ischemic stroke (when a blood clot blocks blood flow to the brain). The medication is given along with standard stroke treatment to see if it helps people recover better. Researchers are comparing this new treatment to , another medication sometimes used for stroke.
Ischemic stroke causes immediate brain damage that needs rapid treatment. While doctors have proven treatments to restore blood flow, there is a need for additional medications that might protect the brain and help patients recover better in the critical first days and weeks after stroke.
You likely qualify if…
You likely don't qualify if…
If you are in the treatment group, you will receive the medication through an IV twice daily for 10 days while in the hospital, then take tablets by mouth three times daily for 60 days at home. If you are in the comparison group, you will take tablets for 5 days. Both groups will have regular hospital visits and tests (blood work, scans, neurological exams) to measure how well you are recovering and to check for any side effects. The entire study lasts about 70 days from enrollment.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Russia